Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

These Stocks Have Tripled This Year
These Stocks Have Tripled This Year
The stock market has made a lot of people rich since 2009, as several major benchmarks have tripled or even quadrupled during the past eight years. Yet for individual stocks, gains can come a lot....
3 Healthcare Stocks I'll Hold Forever
3 Healthcare Stocks I'll Hold Forever
Fund managers who need to look busy might hate to admit it, but doing nothing is usually the best course of action for most investors. That doesn't mean it's a good idea to look the other way when....
3 Healthcare Stocks I'll Hold Forever
3 Healthcare Stocks I'll Hold Forever
Fund managers who need to look busy might hate to admit it, but doing nothing is usually the best course of action for most investors. That doesn't mean it's a good idea to look the other way when....
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?
It may not get the attention as often as larger-cap biotech stocks like Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD), but a bunch of recent drug approvals could soon change that
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?
It may not get the attention as often as larger-cap biotech stocks like Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD), but a bunch of recent drug approvals could soon change that
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?
It may not get the attention as often as larger-cap biotech stocks like Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD), but a bunch of recent drug approvals could soon change that
Here's Why Horizon Pharma Gained as Much as 13.1% Today
Here's Why Horizon Pharma Gained as Much as 13.1% Today
Shares of rare disease biopharma Horizon Pharma (NASDAQ: HZNP) surged over 13% today after the law firm of Green, Griffith successfully asserted one of the company's patents covering Pennsaid 2%
How Safe Is Johnson & Johnson's Dividend?
How Safe Is Johnson & Johnson's Dividend?
Johnson & Johnson (NYSE: JNJ) is one of the best-known companies in America, with most consumers making its over-the-counter products a staple of their medicine cabinets. Yet Johnson & Johnson has
How Safe Is Johnson & Johnson's Dividend?
How Safe Is Johnson & Johnson's Dividend?
Johnson & Johnson (NYSE: JNJ) is one of the best-known companies in America, with most consumers making its over-the-counter products a staple of their medicine cabinets. Yet Johnson & Johnson has
The 3 Best Stocks in Healthcare
The 3 Best Stocks in Healthcare
If you're looking for great investing opportunities, you really need to check out healthcare stocks. From biotech to health insurance to medical devices, there are plenty of solid choices. But which
3 Reasons to Buy Aurinia Pharmaceuticals Stock Right Now
3 Reasons to Buy Aurinia Pharmaceuticals Stock Right Now
Aurinia Pharmaceuticals (NASDAQ: AUPH) has emerged as one of the hottest biotechs on the market this year. Its stock has tripled in value so far in 2017. And that's after a significant pullback of
Opko Health's Biggest Believer: CEO Phillip Frost Puts His Money Where His Mouth Is
Opko Health's Biggest Believer: CEO Phillip Frost Puts His Money Where His Mouth Is
Opko Health (NASDAQ: OPK) stock is down more than 30% so far in 2017. Its share price dropped 7% last year. But if you think the poor performance has caused the company's largest investor to lose
Up in Smoke: This Marijuana Stock Lost More Than Half Its Value Last Week
Up in Smoke: This Marijuana Stock Lost More Than Half Its Value Last Week
As a whole, marijuana stocks are on fire. Through about mid-July, the average marijuana stock was up over 300% on a trailing-12-month basis, albeit one stock with a 2,363% gain at the time had skewed
3 Dividend Healthcare Stocks
3 Dividend Healthcare Stocks
The rapid aging of the world's population should ensure that demand for healthcare products and services remains on the rise for decades to come. But how can income investors take advantage of the
3 Game-Changing Small-Cap Healthcare Stocks
3 Game-Changing Small-Cap Healthcare Stocks
The ability to shake up patient treatment could mean big bucks for Tetraphase Pharmaceuticals (NASDAQ: TTPH), NovoCure (NASDAQ: NVCR), and Exact Sciences (NASDAQ: EXAS). Should you be buying shares in
One Company That's Set to Win From Precision Medicine
One Company That's Set to Win From Precision Medicine
In the last few decades, incredible strides have been made in genome typing and precision medicine technology. What used to cost hundreds of thousands of dollars is now available for $100, opening up
One Company That's Set to Win From Precision Medicine
One Company That's Set to Win From Precision Medicine
In the last few decades, incredible strides have been made in genome typing and precision medicine technology. What used to cost hundreds of thousands of dollars is now available for $100, opening up
One Company That's Set to Win From Precision Medicine
One Company That's Set to Win From Precision Medicine
In the last few decades, incredible strides have been made in genome typing and precision medicine technology. What used to cost hundreds of thousands of dollars is now available for $100, opening up
Why Gilead Sciences Might Not Make an Oncology Acquisition
Why Gilead Sciences Might Not Make an Oncology Acquisition
Is Gilead Sciences (NASDAQ: GILD) backing away from its plans to acquire a smaller biotech focusing on oncology? That could be the case. Gilead CEO John Milligan reportedly told Leerink analyst
Why Gilead Sciences Might Not Make an Oncology Acquisition
Why Gilead Sciences Might Not Make an Oncology Acquisition
Is Gilead Sciences (NASDAQ: GILD) backing away from its plans to acquire a smaller biotech focusing on oncology? That could be the case. Gilead CEO John Milligan reportedly told Leerink analyst
Why Gilead Sciences Might Not Make an Oncology Acquisition
Why Gilead Sciences Might Not Make an Oncology Acquisition
Is Gilead Sciences (NASDAQ: GILD) backing away from its plans to acquire a smaller biotech focusing on oncology? That could be the case. Gilead CEO John Milligan reportedly told Leerink analyst
Why I Love Celgene Corporation
Why I Love Celgene Corporation
Stocks aren't like children. It's not a problem at all if you don't love each stock in your investment portfolio equally. You can have favorites without even the smallest amount of guilt.In my case
3 Stocks That Could Make You Rich
3 Stocks That Could Make You Rich
Railroads. Automobiles. Personal computers. The internet.What do all these things have in common? They're all examples of innovations from the past that have created huge new industries -- and made
3 Stocks That Could Make You Rich
3 Stocks That Could Make You Rich
Railroads. Automobiles. Personal computers. The internet.What do all these things have in common? They're all examples of innovations from the past that have created huge new industries -- and made
3 Stocks That Could Make You Rich
3 Stocks That Could Make You Rich
Railroads. Automobiles. Personal computers. The internet.What do all these things have in common? They're all examples of innovations from the past that have created huge new industries -- and made